In such settings, it should be noted that while BCRP inhibitors may sensitize cancer cells to TAK-243, they may also lead to a narrower therapeutic window by exposing cells, normally protected from xenobiotics by high BCRP expression, to higher concentrations of the drug (48, 49). The gene discussed is ABCG2; the disease is cancer.